



Information on share buy-back programme

On 30 June, 2023, Gubra A/S ("**Gubra**" or the "**Company**") announced that a share buy-back programme of approximately DKK 2.5 million and up to a maximum of 27,231 shares has been initiated with the purpose of meeting the Company's obligations arising from its share-based incentive programmes for employees of the Company.

Today, Gubra announces that 1,539 shares have been repurchased of the share buy-back programme. The details for each transaction made under the share buy-back programme is attached to this announcement. The repurchase of shares is expected to be resumed after the publication of the first half-year report 2023 (will be published on 25 August 2023).

With the transactions carried out under the programme, Gubra owns a total of 33,579 own shares, corresponding to 0.2% of the share capital of the Company. The total amount of shares in the company is 16,349,703 including treasury shares.

Contacts at Gubra

Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586
Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Gubra

Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen in 2023, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

Attachments

[Information on share buy-back programme](#)
[Gubra 30 Jun 2023 28 Jul 2023 Shares Repurchased](#)